2015 Fiscal Year Final Research Report
Clinical development of the next-generation cancer immunotherapy against lung adenocarcinoma
| Project/Area Number |
26830117
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Tumor therapeutics
|
|---|
| Research Institution | Kawasaki Medical School |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Keywords | 肺癌 / がん精巣抗原 / 抗体 / がん免疫 |
|---|
| Outline of Final Research Achievements |
XAGE is a cancer/testis antigen expressed mainly in non-small cell lung cancer. In this study, we investigated correlation of intensity of humoral and cellular immune responses against XAGE1 and its clinical relevance. Frequency of XAGE1 antibody positive patients in NSCLC was 9.2% (46/500).The frequencies of Th1 and Th17 were significantly higher and immunosuppressive populations as activated Tregs and MDSC were significantly lower in antibody positive patients compared to antibody negative patients. Median OS were 31.5 and 15.6 months in antibody-positive and negative patients (P=0.006) with 145 stage IIIB/IV lung adenocarcinoma. Multivariable analyses showed XAGE1 antibody response was independent prognostic factor. Our findings indicate that XAGE1 antibody response is a prognostic biomarker in the patients with advanced lung adenocarcinoma.
|
| Free Research Field |
腫瘍免疫
|
